Furthermore, we found that the chemokine receptor CXCR5 was significantly decreased in COVID-19 patients, which might lead to inhibition of germinal center reactions and the dysregulated humoral immune responses observed in the early stage of SARS-CoV-2 infection.30 The gene discussed is CXCR5; the disease is COVID-19.